Royalty Pharma plc (RPRX) — Financial statements
Income statement, balance sheet, and cash flow for Royalty Pharma plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,378↑5.1% | 2,264↓3.9% | 2,355↑5.2% | 2,237↓2.3% | 2,289 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 2,378↑5.1% | 2,264↓3.9% | 2,355↑5.2% | 2,237↓2.3% | 2,289 | |
| Operating Expenses | ||||||
| R&D Expenses | 452↑22500.0% | 2↓96.2% | 52↓70.6% | 177↓11.5% | 200 | |
| General & Administrative Expenses | 573↑142.3% | 237↓5.2% | 250↑9.9% | 227↑24.3% | 183 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 573↑142.3% | 237↓5.2% | 250↑9.9% | 227↑24.3% | 183 | |
| Other Expenses | -207↓128.2% | 732↑30.6% | 561↓63.3% | 1,526↑220.6% | 476 | |
| Operating Expenses | 819↓15.7% | 971↑12.6% | 862↓55.3% | 1,930↑124.8% | 859 | |
| Total Costs & Expenses | 819↓15.7% | 971↑12.6% | 862↓55.3% | 1,930↑124.8% | 859 | |
| Operating Results | ||||||
| Operating Income | 1,560↑20.7% | 1,292↓13.4% | 1,492↑385.9% | 307↓78.5% | 1,431 | |
| Depreciation & Amortization | 4 | 0.00 | 0.00↓100.0% | 6↓75.3% | 23 | |
| EBITDA | 1,636↑5.1% | 1,556↓17.5% | 1,887↑345.4% | 424↓70.4% | 1,430 | |
| EBIT | 1,632↑4.9% | 1,556↓17.5% | 1,887↑351.5% | 418↓70.3% | 1,407 | |
| Interest & Other Income | ||||||
| Net Interest Income | -274↓53.8% | -178↓55.1% | -115↓4.8% | -110↑2.6% | -113 | |
| Interest Income | 34↓29.0% | 47↓34.5% | 72↓7.7% | 78↑46.3% | 54 | |
| Interest Expense | 308↑36.4% | 226↑20.5% | 187↓0.4% | 188↑13.1% | 166 | |
| Non-Operating Income | -72↑72.6% | -264↑33.2% | -395↓256.1% | -111↓574.8% | 23 | |
| Other Income / Expenses | -235↓713.3% | 38↓81.5% | 208↑370.0% | -77↑59.4% | -190 | |
| Income Before Tax | 1,324↓0.5% | 1,331↓21.7% | 1,700↑639.0% | 230↓81.5% | 1,241 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 1,324↓0.5% | 1,331↓21.7% | 1,700↑639.0% | 230↓81.5% | 1,241 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 771↓10.2% | 859↓24.3% | 1,135↑2549.5% | 43↓93.1% | 620 | |
| Bottom-Line Net Income | 1,006↓11.5% | 1,136↓25.6% | 1,528↑3466.4% | 43↓93.1% | 620 | |
| EPS (Basic) | 2.33↑21.4% | 1.92↓43.7% | 3.41↑3310.0% | 0.10↓93.3% | 1.49 | |
| EPS (Diluted) | 1.80↓5.8% | 1.91↓24.5% | 2.53↑2430.0% | 0.10↓93.3% | 1.49 | |
| Weighted Average Shares | 432↓3.2% | 446↓0.4% | 448↑2.2% | 438↑5.6% | 415 | |
| Weighted Average Diluted Shares | 560↓5.8% | 594↓1.5% | 603↑6.7% | 565↑36.2% | 415 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.